Drug intelligence / Profile preview

AH002

Development stage: Preclinical
Lead developer: Apricity Health
Administration: Inhalation

Overview

AH002 is a preclinical-stage precision oncology drug candidate being developed by Apricity Health. It is part of a pipeline of therapies designed to treat cancer patients who have developed resistance to current standard-of-care treatments. The discovery of AH002 was driven by Apricity Health's proprietary platform, which utilizes real-world data to identify novel targets and blood-based biomarkers for patient selection. The program aims to utilize a dynamic precision clinical trial design to improve outcomes in patient populations that do not respond to existing therapies.

Beyond the preview

Go deeper on AH002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AH002.

Explore the full profile